findmyKOL
Clinical trialNCT05297864TerminatedPhase 2Interventional

PARP Inhibition for Gliomas (PI-4G or π4g)

SponsorUniversity of OklahomaEnrollment15Recurrent AstrocytomaRecurrent GlioblastomaRecurrent GliomaRecurrent Oligodendroglioma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Niraparib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Jun 2022
Primary completion
14 Nov 2023
Completion
6 Feb 2024
Last update posted
23 May 2025
Registered enrollment
15
Registry id
NCT05297864
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.